Trial · NCT03330197
Results by group94
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 94
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Safety and Tolerability of Intratumoral Ad-RTS-hIL-12 and Veledimex as Measured by Dose Limiting Toxicities and Compliance. | Arm 1 - Closed | DLTs | 0 | Participants | |
| The Safety and Tolerability of Intratumoral Ad-RTS-hIL-12 and Veledimex as Measured by Dose Limiting Toxicities and Compliance. | Arm 2 - Closed | DLTs | 1 | Participants | |
| The Safety and Tolerability of Intratumoral Ad-RTS-hIL-12 and Veledimex as Measured by Dose Limiting Toxicities and Compliance. | Arm 1 - Closed | AE leading to death | 0 | Participants | |
| The Safety and Tolerability of Intratumoral Ad-RTS-hIL-12 and Veledimex as Measured by Dose Limiting Toxicities and Compliance. | Arm 2 - Closed | AE leading to death | 0 | Participants | |
| The Safety and Tolerability of Intratumoral Ad-RTS-hIL-12 and Veledimex as Measured by Dose Limiting Toxicities and Compliance. | Arm 1 - Closed | AEs leading to study discontinuation | 0 | Participants | |
| The Safety and Tolerability of Intratumoral Ad-RTS-hIL-12 and Veledimex as Measured by Dose Limiting Toxicities and Compliance. | Arm 2 - Closed | AEs leading to study discontinuation | 0 | Participants | |
| The Safety and Tolerability of Intratumoral Ad-RTS-hIL-12 and Veledimex as Measured by Dose Limiting Toxicities and Compliance. | Arm 1 - Closed | AEs leading to study treatment discontinuation | 0 | Participants | |
| The Safety and Tolerability of Intratumoral Ad-RTS-hIL-12 and Veledimex as Measured by Dose Limiting Toxicities and Compliance. | Arm 2 - Closed | AEs leading to study treatment discontinuation | 1 | Participants | |
| The Safety and Tolerability of Intratumoral Ad-RTS-hIL-12 and Veledimex as Measured by Dose Limiting Toxicities and Compliance. | Arm 1 - Closed | AE leading to leading to study treatment dose reduction | 0 | Participants | |
| The Safety and Tolerability of Intratumoral Ad-RTS-hIL-12 and Veledimex as Measured by Dose Limiting Toxicities and Compliance. | Arm 2 - Closed | AE leading to leading to study treatment dose reduction | 0 | Participants | |
| The Safety and Tolerability of Intratumoral Ad-RTS-hIL-12 and Veledimex as Measured by Dose Limiting Toxicities and Compliance. | Arm 1 - Closed | Adverse events leading to study treatment dose interruption | 1 | Participants | |
| The Safety and Tolerability of Intratumoral Ad-RTS-hIL-12 and Veledimex as Measured by Dose Limiting Toxicities and Compliance. | Arm 2 - Closed | Adverse events leading to study treatment dose interruption | 1 | Participants | |
| The Safety and Tolerability of Intratumoral Ad-RTS-hIL-12 and Veledimex as Measured by Dose Limiting Toxicities and Compliance. | Arm 1 - Closed | Treatment emergent adverse events | 3 | Participants | |
| The Safety and Tolerability of Intratumoral Ad-RTS-hIL-12 and Veledimex as Measured by Dose Limiting Toxicities and Compliance. | Arm 2 - Closed | Treatment emergent adverse events | 2 | Participants | |
| To Measure the Veledimex in Blood and Brain Tumor by Using the LC-MS Method | Arm 1 - Closed | Brain tumor results (Day 0) | 0.172 | Full Range 0.1 to 0.211 | ng/mL |
| To Measure the Veledimex in Blood and Brain Tumor by Using the LC-MS Method | Arm 2 - Closed | Brain tumor results (Day 0) | NA | Full Range NA to NA | ng/mL |
| To Measure the Veledimex in Blood and Brain Tumor by Using the LC-MS Method | Arm 1 - Closed | Day 0 time of resection - veledimex plasma PK | 1.40 | Full Range 1.00 to 1.86 | ng/mL |
| To Measure the Veledimex in Blood and Brain Tumor by Using the LC-MS Method | Arm 2 - Closed | Day 0 time of resection - veledimex plasma PK | NA | Full Range NA to NA | ng/mL |
| To Measure the Veledimex in Blood and Brain Tumor by Using the LC-MS Method | Arm 1 - Closed | Day 1 predose- veledimex plasma PK | 1.02 | Full Range 1 to 1.07 | ng/mL |
| To Measure the Veledimex in Blood and Brain Tumor by Using the LC-MS Method | Arm 2 - Closed | Day 1 predose- veledimex plasma PK | NA | Full Range NA to NA | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03330197/results